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ABSTRACT
Modified bases, such as O
6-methylguanines, are pro-
ducedincellsexposedtoalkylatingagentsandcause
apoptosis. In human cells treated with N-methyl-
N-nitrosourea, we detected a protein complex com-
posed of MutSa, MutLa and PCNA on damaged
DNA by immunoprecipitation method using chro-
matin extracts, in which protein–protein interactions
werestabilizedbychemicalcrosslinking.Timecourse
experimentsrevealedthatMutSa,consistingofMSH2
and MSH6 proteins, and PCNA bind to DNA to form
an initial complex, and MutLa, composed of MLH1
and PMS2, binds to the complex when the DNA is
damaged. This sequential mode of binding was fur-
ther confirmed by the findings that the association of
PCNA–MutSa complex on chromatin was observed
even in the cells that lack MLH1, whereas in the
absence of MSH2 no association of MutLa with the
chromatin was achieved. Moreover, reduction in
the PCNA content by small-interfering RNA or inhibi-
tion of DNA replication by aphidicolin, an inhibitor
of DNA polymerase, significantly reduced the levels
of the PCNA–MutSa–MutLa complex and also
suppressed an increase in the caspase-3 activity,
a hallmark for the induction of apoptosis. These
observations imply that the induction of apoptosis
is coupled with the progression of DNA replication
through the action of PCNA.
INTRODUCTION
Base mismatches are constantly produced at low levels during
the normal process of DNA replication and cause base sub-
stitution mutations if they are not repaired. The occurrence of
such events isaccelerated whenthe cells are exposedtocertain
agents that modify DNA bases. O
6-methylguanine, produced
by the action of alkylating agents, is one such lesion; it can
pair with thymine as well as cytosine during DNA replication,
leading to a G·C to A·T transition (1,2). To prevent such
outcomes, organisms from bacteria to human are equipped
with a speciﬁc DNA repair enzyme, O
6-methylguanine-
DNA methyltransferase, which transfers a methyl group
from the O
6-methylguanine moiety of the alkylated DNA
to its own molecule, thereby repairing the DNA lesion in a
single-step reaction (3,4). MGMT
 /  mice, which are defect-
ive in the methyltransferase gene, are hypersensitive to the
killing effect of alkylating agents and, when administered
sublethal doses of the agents, produce a large number of
tumors in their organs (5,6). In these mice, the damage by
the alkylating agents is conﬁned to tissues with rapidly grow-
ing cells, such as those in the bone marrow and intestinal
mucosa, indicating that cell proliferation is required for killing
the cells containing O
6-methylguanine in the DNA. Studies
with MGMT
 /  cells further revealed that the O
6-methylguan-
ine-induced cell death occurs by apoptosis, which requires at
least one round of DNA replication for its induction (7–9).
Another notable feature of O
6-methylguanine-induced
apoptosis is the involvement of mismatch repair proteins in
the process. Mismatch repair has been deﬁned as a mechanism
to correct replication errors, including mismatched bases and
small insertions/deletions, by excising the error-containing
region of the newly replicated strand, followed by repair
synthesis and strand rejoining. The molecular mechanism of
mismatch repair has been well characterized in Escherichia
coli, in which at least 11 enzymes or protein components are
involved (10). Among them, MutS and MutL play important
roles in recognizing mismatched regions and initiating the
repair reactions. Many mammalian counterparts of MutS
and MutL have been found, among which MutSa, a hetero-
dimer composed of the MutS homologs MSH2 and MSH6,
and MutLa, a dimer composed of the MutL homologs MLH1
*To whom correspondence should be addressed. Tel: +81 6 6872 8216; Fax: +81 6 6872 8210; Email: hidaka@beri.or.jp
  The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 17 5703–5712
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of base mismatches (11–14). Early studies with cell lines
derived from human tumors revealed that the lack of some
of these gene functions rendered O
6-methylguanine-DNA
methyltransferase-deﬁcient cells resistant to alkylating agents
(15,16). Although tumor-derived cells would possess muta-
tions and exhibit transcriptional silencing of some other genes,
recent studies with a more deﬁned system, namely MGMT
 / 
MLH1
 /  cells derived from the gene-targeted mice, have
clearly shown that the mismatch repair-related function is
indeed required for the execution of apoptosis triggered by
O
6-methylguanine (17,18).
In eukaryotic cells, the mismatch repair proteins appear to
be involved in at least two different processes, one to repair
replication-associated errors in a strand-speciﬁc manner and
the other to signal for inducing apoptosis in cells with
mismatched DNA bases. This was clearly shown by recent
ﬁndings that certain MSH2 or MSH6 missense mutations can
cause a deﬁciency in mismatch repair, whereas retaining the
signaling functions that confer sensitivity to chemotherapeutic
agents (19,20). The molecular mechanism of the former pro-
cess, mismatch repair, has been elucidated by analyzing the
interactions and reconstructing the protein complex in vitro
(21,22). However, studies on the mechanism of the latter pro-
cess, modiﬁed base-induced apoptosis, have been hampered
mainly by the lack of appropriate systems for investigating
the process occurring in cells. In this regard, human cell lines
defective in the MGMT gene would be noteworthy, since
the exposure of the cells to simple alkylating agents
would induce a large number of O
6-methylguanine lesions
in the chromosomal DNA, which would trigger apoptosis.
The O
6-methylguanine thus formed would persist in the
DNA through the progression of the cell cycle and, hence,
the conditions and timing required for the formation of
an apoptosis-related protein complex could be followed
in the cells. Moreover, by comparing the results obtained
with O
6-methylguanine-DNA methyltransferase-proﬁcient
and -deﬁcient cells, it is possible to ascertain if the molecular
events observed are related to O
6-methylguanine (23,24).
Taking advantage of this system, we have investigated
an early step of apoptosis triggered by O
6-methylguanine.
Since the protein complex formed on O
6-methylguanine-
containing DNA is unstable, to stabilize the multi-protein
complex formed on the chromatin, we treated cells undergoing
the early process of apoptosis with a protein crosslinking
agent. After the isolation of the complex, the crosslinks
were cleaved and its components were analyzed. In this way,
we were able to determine the nature of the complex and
resolve the conditions and timing required for its formation.
MATERIALS AND METHODS
Cell lines and cell culture
Human cell lines, HeLa S3 (wild-type), and its O
6-methyl-
guanine-DNA methyltransferase-deﬁcient derivative, HeLa
MR (25), were obtained from H. Hayakawa (Kyushu Univer-
sity, Fukuoka, Japan). SW48, a human tumor-derived cell line
deﬁcient in both Mgmt and Mlh1 expression, was purchased
from American Type Culture Collection. LoVo, a human
colorectal adenocarcinoma cell line deﬁcient in Msh2 (26),
was obtained from S. Oda (National Kyushu Cancer Center,
Fukuoka, Japan). The HeLa MR line stably expressing FLAG
epitope-tagged PMS2 was constructed as follows. A DNA
fragment encoding the hPMS2 protein was ampliﬁed by
PCR using pcDNA3.1/V5-His-hPMS2 plasmid DNA (27),
obtained from S. Fukushige (Tohoku University School of
Medicine, Miyagi, Japan), as a template and was inserted
into the HindIII–BamHI site of the p3xFLAG-CMV-10
expression vector (Sigma). The resulting plasmid, named
p3xFLAG-hPMS2, was digested with ScaI, and the linearized
DNA was introduced into HeLa MR cells by electroporation
using a Genepulser (Bio-Rad). Stable transfectants were
selected as G418 (700 mg/ml) resistant colonies, and a line
expressing the FLAG-tagged hPMS2 protein was isolated
and designated as HeLa MR (ePMS2). These cells were
cultured in DMEM supplemented with 10% fetal bovine
serum (FBS) and antibiotics at 37 C in a 5% CO2 atmosphere.
Chemicals
N-Methyl-N-nitrosourea (MNU) and 3,30-dithiobis-
sulfosuccinimidylpropionate (DTSSP) were obtained from
Nacalai Tesque Inc. (Kyoto, Japan) and Pierce, respectively.
O
6-benzylguanine and aphidicolin were purchased
from Sigma.
Preparation of whole cell extracts
The cells were washed twice with phosphate-buffered saline
(PBS) and scraped from the dish. The collected cells by cent-
rifugation at 3000 g for 5 min at 4 C were suspended with
2· SDS–PAGE sample buffer [120 mM Tris–HCl (pH 6.8),
4% SDS, 20% glycerol, 200 mM DTT and 0.002% bro-
mophenol blue], sonicated and boiled. The material was cent-
rifuged at20000gfor10min,andthesupernatantfraction was
taken as the whole cell extract.
Preparation of chromatin extracts
Approximately 3 · 10
6 cells were seeded in a 10 cm dish and
incubated for 1 day. The cells were washed twice with PBS
and then treated with 1 mM MNU in serum-free DMEM for
1 h. After the medium was replaced with DMEM containing
10% FBS, the cells were incubated for the appropriate dura-
tion. The cells were permeabilized and washed extensively
on the dish with ice-cold buffer A [20 mM HEPES–KOH
(pH 7.9), 5 mM KCl, 1.5 mM MgCl2, 0.25 M sucrose and
0.1 mM EGTA] containing 50 mg/ml of digitonin (Wako) and
protease inhibitors (Roche), and then were treated with 1 mM
DTSSP (Pierce) for 2 h at 4 C. The crosslinking reaction was
stoppedby theadditionof50 mMTris–HCl(pH 7.5).The cells
were scraped from the dish and collected by centrifugation
at 3000 g for 10 min at 4 C. The cell pellet was suspended in
ice-cold buffer B [20 mM Tris–HCl (pH 8.0), 0.1 M NaCl,
1.5 mM MgCl2, 10% glycerol and 0.1% Triton X-100]
containing protease inhibitors and then was sonicated. The
material was centrifuged at 20000 g for 15 min at 4 C, and
the supernatant fraction was taken as the chromatin extract.
Immunoprecipitation and western blotting
For the immunoprecipitation of the FLAG-tagged PMS2-
bound proteins, 10 ml of anti-FLAG M2-agarose (Sigma)
were added to 1 ml of chromatin extract, prepared as described
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of the beads with buffer B, the proteins bound to the beads
were eluted in 40 ml of buffer B containing 200 mg/ml of 3·
FLAG peptide (Sigma). To immunoprecipitate the proteins
bound to MSH2 or PMS2, 10 ml of anti-MSH2 (Zymed) or
anti-PMS2 antibody conjugated with Protein G–Sepharose
(Amersham Biosciences) were mixed with the chromatin
extract in a similar manner as described, and proteins
bound to the beads were eluted with SDS–PAGE sample
buffer [60 mM Tris–HCl (pH 6.8), 2% SDS, 10% glycerol,
100 mM DTT and 0.001% bromophenol blue]. The anti-PMS2
antibody was raised in a rabbit immunized with puriﬁed pro-
tein covering the entire length of human PMS2 expressed in
E.coli and then was afﬁnity-puriﬁed using the antigen. The
speciﬁcity of the antibody was conﬁrmed by immunoblotting
(data not shown). Conjugation of the antibody to Protein G
beads was carried out as described previously (28). Appropri-
ate amounts of the eluted samples were subjected to SDS–
PAGE and electroblotted onto a PVDF membrane (Bio-Rad).
Detection was performed with an ECL Advance western
blotting detection kit (Amersham Biosciences). The primary
antibodies used were as follows: anti-FLAG M2 (Sigma), anti-
MLH1 (BD Biosciences), anti-MSH2 (Zymed), anti-MSH6
(BD Biosciences), anti-PCNA (Santa Cruz Biotechnology)
and anti-Histone H3 (abcam). Anti-mouse IgG and anti-
rabbit IgG conjugated to horseradish peroxidase (Amersham
Biosciences) were used as the secondary antibody.
siRNA transfection
siRNA for the PCNA sequence (siPCNA), 50-AAGCAC-
CAAACCAGGAGAAAG-30, was purchased from Qiagen.
After culturing 1 · 10
6 cells in a 10 cm dish for 1 day, the
cells were transfected with 40 nM of siRNA, using the
Lipofectamine2000 reagent (Invitrogen) according to
the manufacturer’s protocol. For the control transfection,
the negative control siRNA (Qiagen) was used.
Assay of caspase-3 activity
One day after the siRNA transfection, the cells (1–5 · 10
5)
were seeded in a 6 cm dish and incubated at 37 C for 1 day.
The cells were treated with 1 mM MNU for 1 h and incubated
for another 3 days. The cell lysate preparation and the caspase
activity assay were performed, according to the instructions in
the EnzChek caspase-3 assay kit #2 (Molecular Probes). To
assay the caspase-3 activity, the rate of hydroxylation of the
synthetic substrate Z-DEVD-R110 was measured in the pres-
ence or absence of the inhibitor, Ac-DEVD-CHO. The hydro-
lysis products were quantiﬁed using a spectroﬂuorometer,
Fusion a (PerkinElmer), with excitation at 496 nm and emis-
sion at 520 nm. The values obtained with the inhibitor were
subtracted from those obtained without the inhibitor to express
the speciﬁc activity of caspase-3.
Flow cytometric analysis
Cells (1 · 10
6) on a 10 cm dish were harvested by a 0.25%
trypsin–0.02% EDTA treatment, washed with PBS and
suspended in 400 ml of PBS containing 0.1% Triton X-100,
25 mg/ml of propidium iodide and 0.1 mg/ml of RNase A.
Samples were analyzed using a FACS Calibur ﬂow cytometer
(Becton Dickinson), with 10000 events per determination.
RESULTS
Formation of a protein complex on
O
6-methylguanine-containing DNA
Accumulating evidence suggests that an initial step in the
apoptosis induced by O
6-methylguanine would be the binding
of mismatch recognition proteins to the DNA with the lesion.
However, it was difﬁcult to isolate such a protein–DNA com-
plex from the cells, since it is unstable and decomposed during
ordinary extraction procedures. To overcome this difﬁculty,
we treated the cells with a crosslinking agent, before the
materials were isolated. The cells were permeabilized with
digitonin and then treated with DTSSP, to stabilize the com-
plex. After sonication of the cells, the chromatin was extracted
and then the crosslinks were cleaved by a treatment with a
reducing agent. In this way, we were able to resolve the com-
ponents of the complex and follow the conditions needed for
its formation.
O
6-methylguanine, which is produced in DNA by treating
cells with simple alkylating agents, can be repaired by a spe-
ciﬁc DNA repair enzyme, O
6-methylguanine-DNA methyl-
transferase. HeLa MR cells are defective in this enzyme
and readily undergo apoptosis after exposure to relatively
low doses of MNU. We used this cell line and its parental
line, HeLa S3, which is proﬁcient in the methyltransferase
activity, to determine whether a protein–DNA complex is
formed in an O
6-methylguanine-dependent manner. The two
types of cells were treated with 1 mM MNU for 1 h and
incubated in MNU-free growth medium for another 11 h,
and then the cellswere collectedfor examinationof the protein
complexes. From the same amounts of chromatin fractions
prepared from each sample, DTSSP-linked protein complexes
were immunoprecipitatedwith the use ofan anti-MSH2mono-
clonal antibody, and then the protein components were disso-
ciated by the treatment with the reducing agent. The materials
thus obtained were subjected to SDS–PAGE, followed by the
detection of each component by speciﬁc antibodies.
Figure 1 shows analyses of the MSH2-bound protein com-
ponents on the chromatin DNA of the two types of cells, with
or without MNU treatment. In HeLa MR cells without MNU
treatment, certain amounts of MSH6 and PCNA were co-
precipitated with MSH2, indicating that low, but signiﬁcant
amounts of MutSa as well as PCNA are associated with the
chromatin, even under normal conditions. When the cells were
exposedtoMNU, the association ofthesecomponents with the
chromatin increased, and moreover, new bands, corresponding
to MLH1 and PMS2, appeared. Since only very low signals for
these proteins were detected in untreated cells, it is likely that
the association of MutLa with the chromatin is strictly
dependent on the formation of O
6-methylguanine in the
DNA. This notion is supported by the results obtained with
HeLa S3 cells, in which the O
6-methylguanine is repaired
efﬁciently by its intrinsic repair enzyme activity. With and
without MNU treatment, there were no signiﬁcant changes in
the patterns of these protein bands.
Association of the protein components with
chromatin after MNU treatment
To address this hypothesis for the complex formation on the
damaged chromosome in detail, we constructed HeLa MR
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produced about twice as much of the FLAG-PMS2 as the
endogenous PMS2 protein (data not shown). We ﬁrst used
this strain, named HeLa MR (ePMS2), to check whether
the amounts of protein components of the mismatch recogni-
tion complex increase by the treatment of MNU. As shown in
Figure 2A and B, immunoblotting experiments using whole
cell extracts clearly indicates that the amounts of mismatch
repair proteins and PCNA are almost constant during times
even after MNU treatment. We then monitored the amounts of
these proteins that are bound to chromatin. As shown in
Figure 2C and D, dramatic increases in the levels of MLH1
and FLAG-tagged PMS2, the components of MutLa, were
observed in the chromatin extracts upon the treatment of
MNU. Such increases were also shown in HeLa MR cells,
ruling out the possibility that this is due to the effect of the
exogenous expression of FLAG-PMS2 protein in HeLa MR
(ePMS2) cells (data not shown). PCNA increases moderately
and MSH2 and MSH6, the components of MutSa, do slightly.
The observations suggest that the association of these proteins
with the damaged chromatin is induced, without changing the
total amounts of the proteins, after MNU treatment.
Time course of the complex formation after
MNU treatment
To follow the process of the protein complex formation on the
damaged chromosome, we used the chromatin extracts at each
time point (Figure 2C) for immunoprecipitation experiments.
First, an anti-MSH2 antibody was employed and the proteins
interacting with MSH2 were detected by immunoblotting
(Figure 3A). Without MNU treatment, certain amounts of
PCNA and the two components of MutSa, MSH2 and
MSH6, were detected, and the amounts of these proteins
increased slightly with the progression of cell growth. Signi-
ﬁcant increases in the amounts of these proteins were observed
after MNU administration, and MLH1 and PMS2, the latter of
which was FLAG-tagged, in the complex increased rapidly
and concomitantly up to 12 h after the MNU treatment
(Figure 3A and B). It seems that certain amounts of MutSa
and PCNA are associated with the normal form of the chro-
matin, and when the DNA is damaged, MutLa, composed of
MLH1 and PMS2, is further bound to the complex.
To monitor the time course of formation of the complex,
the chromatin-associated PMS2 was immunoprecipitated
with the use of its FLAG-tag, and the components of the
mismatch protein complex were examined. As shown in
Figure 3C and D, relatively small amounts of PMS2 were
present on the chromatin without the MNU treatment, and
the associations of the other components with PMS2 were
hardly detected. After the MNU treatment, the amounts of
the PMS2-associated forms of the protein components
increased dramatically and reached a maximum level at the
12 h of treatment, consistent with the observation made in the
preceding experiment (Figure 3B). Thus, the sequential
binding of MutSa and MutLa was indicated by the recipro-
cal immunoprecipitation experiments using the chromatin
extracts.
Mutations affecting the complex formation
To conﬁrm this notion, we examined the complex formation in
various cell lines with defects in some of the mismatch repair
proteins. The cell line SW48, derived from a human colorectal
adenocarcinoma, is deﬁcient in O
6-methylguanine-DNA
methyltransferase activity and lacks the MLH1 protein,
owing to transcriptional silencing of the genes (29,30). In
immunoprecipitation assays using the same amount of chro-
matin extracts from cells treated with or without MNU, the
MNU-induced interactions of MSH2 with the components of
MutLa, MLH1 and PMS2, were detected in the HeLa MR, but
not in the SW48 (Figure 4A). Moreover, the interaction
between MSH2 and PCNA was observed, regardless of the
MNU treatment, in SW48 as well as in HeLa MR. These
ﬁndings indicate that the MLH1 function is dispensable for
the interaction between MutSa and PCNA on chromatin.
Suppression of the complex formation was observed with
the cell line LoVo, which is defective in the MSH2 function.
Since this cell line has functional O
6-methylguanine-DNA
methyltransferase, the experiment was performed with the
use of O
6-benzylguanine, a speciﬁc inhibitor of the methyl-
transferase (31,32). In the presence of O
6-benzylguanine,
methyltransferase-proﬁcient HeLa S3 cells, which are other-
wisedefectiveinMNU-inducedcomplexformation(Figure1),
were able to produce the complex in response to the MNU
treatment. Under the same conditions, LoVo cells showed no
response to the MNU treatment (Figure 4B). These results
indicate that the complex formation is indeed triggered by
the O
6-methylguanine lesions produced on the chromosomal
DNA and also that the association of MutLa with the chro-
matin is MutSa-dependent.
Role of PCNA in O
6-methylguanine-induced apoptosis
The results of these experiments indicated that PCNA is
concomitantly associated with MutSa on normal chromatin
Figure 1. Formation of a PCNA–MutSa–MutLa complex in
methyltransferase-deficient cells upon exposure to MNU. HeLa MR
(methyltransferase-deficient) and HeLa S3 (methyltransferase-proficient)
cells were incubated in serum-free medium with or without 1 mM MNU for
1 h, and then were placed in 10% FBS-containing medium and incubated
further for 11 h. The cells were treated with hypotonic buffer containing
50 mg/ml of digitonin on the dish and were then collected. After sonication
of the cells, the chromatin extracts were prepared by centrifugation and the
sameamountofextractswereusedforeachimmunoprecipitationassaywithan
anti-MSH2 antibody. The immunoprecipitated materials were separated by
SDS–PAGE and immunoblotted with specific antibodies against the MSH2,
MSH6, MLH1, PMS2 and PCNA proteins.
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complex upon MNU treatment of the cells. To determine
whether PCNA is prerequisite for the complex formation
and if such a complex is involved in the progression of apop-
tosis, we employed the RNA interference method (33). For
this, siPCNA, a siRNA speciﬁc for a part of the PCNA mRNA
sequence, and siCont., a negative control RNA, were synthes-
ized and introduced into HeLa MR (ePMS2) cells. At 48 h
after the application of siPCNA, the cellular level of PCNA
decreased to 39% of the level attained with cells that received
the siCont., whereas the expression levels of other mismatch-
related proteins were not affected (Figure 5A). Then, the
siPCNA-treated cells and control cells were exposed to
1 mM MNU, and the chromatin extracts were prepared
after 12 h for immunoprecipitation. Under PCNA knockdown
conditions, the loading of the mismatch repair proteins to
chromatin was severely inhibited (Figure 5B). A signiﬁcantly
lower amount of FLAG-PMS2 was immunoprecipitated
with an anti-FLAG antibody, as compared with that of the
control cells (Figure 5C). Simultaneously, the amounts of the
PMS2-associated forms of MSH2 and MLH1 decreased to
60% (for MSH2) and 47% (for MLH1) of levels for the con-
trol, respectively. Thus, PCNA is actually required for the
recruitment of the mismatch repair proteins to chromatin
and for the formation of the mismatch recognition complex
on the damaged chromosome. Similar observation was
reported in a cell-free reconstituted system, by using puriﬁed
PCNA, MutSa (MSH2/MSH6) complex and mismatch-
containing heteroduplex DNA (34).
Caspase-3, a member of the cysteine protease family, is
induced during the course of apoptosis, induced by TNF,
gamma rays and many other means (35). This is also the
hallmark of the progression of apoptosis triggered by O
6-
methylguanine; caspase-3 activation occurred in Mgmt-
deﬁcient cells, but not in cells defective in both Mgmt and
Mlh1, when these cells were treated with MNU (18). There-
fore, we next examined whether the caspase-3 induction in
HeLa MR (ePMS2) cells exposed to MNU is affected by the
PCNA knockdown. The result shown in Figure 5D indicates
that the treatment of the cells with siPCNA signiﬁcantly
Figure 2. AssociationoftheproteincomponentswithchromatinafterMNUtreatment.(A)HeLaMR(ePMS2)cellsweretreatedwithorwithout1mMMNUfor1h
and collected at the indicated times and the whole cell extracts were prepared as described in Materials and Methods. Immunoblotting was performed by the use of
antibodiesthatspecificallyrecognizeMSH2,MSH6,MLH1,FLAG-PMS2,PCNAandb-actin.b-Actinisaloadingcontrol.(B)Theintensitiesofthebandsforeach
protein,shownin(A),werequantified,andtherelativeintensitiesascomparedwiththatat0hareplotted.Opensquares,MSH2;opencircles,MSH6;closedsquares,
MLH1;closedcircles,FLAG-PMS2;andopentriangles,PCNA.(C)HeLaMR(ePMS2)cellstreatedinthesamewayin(A)werecollectedandthechromatinextracts
were prepared as described in Figure 1. The amounts of proteins bound to chromatin were analyzed by immunoblotting using specific antibodies against mismatch
repair proteins, PCNA and histone H3. Histone H3 is a loading control. (D) The relative intensities of the bands for each protein, shown in (C), are calculated in the
same way as in (B), and are plotted. Open squares, MSH2; open circles, MSH6; closed squares, MLH1; closed circles, FLAG-PMS2; and open triangles, PCNA.
Nucleic Acids Research, 2005, Vol. 33, No. 17 5707reduced the induction of caspase-3. This implies that PCNA
is a necessary component of the mismatch recognition com-
plex, which is required for the execution of MNU-induced
apoptosis.
Requirement of DNA replication for the recognition
of O
6-methylguanine base pairs
Previous studies with Mgmt-knockout mice (5) revealed that
bone marrow, spleen, thymus and intestinal mucosa, in which
cells are actively growing, are most severely damaged by
MNU administration, implying that DNA replication is
required for O
6-methylguanine-triggered apoptosis. To deter-
mine whether DNA replication is a prerequisite for the forma-
tion of the mismatched base-associated protein complex, we
examined the effects of aphidicolin, an inhibitor of DNA poly-
merase, on the formation of the complex. HeLa MR (ePMS2)
cells were incubated for 16 h in a medium containing aph-
idicolin,toinhibitDNA replication,and then were treated with
MNU for 1 h. The cell culture was divided into two portions;
one incubated in the absence of aphidicolin and the other in the
presence of the drug. The cells were collected at the indicated
times after MNU treatment and were subjected to ﬂow cyto-
metry and immunoprecipitation analyses. As shown in
Figure 6A, most of the cells treated with aphidicolin are arres-
ted at the G1/S boundary and remained at this stage as long as
the drug was present in the medium. When the aphidicolin was
removed, the treated cells progressed into the S phase of the
cell cycles. Immunoblotting analyses of these samples
revealed that total amounts of each mismatch repair protein
and PCNA were almost constant (data not shown); however,
the level of PCNA bound to chromatin remarkably increased
when the cells progressed into S phase (Figure 6B). In accord-
ance with this increase, immunoprecipitation analyses showed
that in the absence of aphidicolin, the association of MSH2,
MLH1 and PCNA with FLAG-tagged PMS2 occurs gradually
when the cells progress into the S phase, whereas the forma-
tion of the complex is severely inhibited when the drug is
present in the medium (Figure 6C). Thus, it seems that the
formation of the mismatch recognition complex induced
by MNU treatment is dependent on the progression of DNA
replication.
Figure3.TimecourseoftheformationofthemismatchrecognitioncomplexafterMNUtreatment.HeLaMR(ePMS2)cellsweretreatedwithorwithout1mMMNU
for 1 h and collected at the indicated times for examination, as described in the legend to Figure 1. (A) Immunoprecipitation with the anti-MSH2 antibody was
performed using the chromatin extracts shown in Figure 2C. Antibodies that specifically recognize MSH2, MSH6, MLH1, FLAG-PMS2 and PCNA were used for
immunoblotting.(B)Theintensitiesofthebandsforeachprotein,shownin(A),werequantified,andtherelativeintensitiesascomparedwiththatat12hwithMNU
treatment(peaksignal)areplottedforeachprotein.ClosedandopencirclesrepresentsignalsobtainedwithandwithoutMNUtreatment,respectively.(C)Thesame
amountsofchromatinextractsfromHeLaMR(ePMS2)cellswereusedforimmunoprecipitationwiththeanti-FLAGantibody,followedbyimmunoblotting.(D)The
relative intensities of the bands for each protein, shown in (C), are calculated in the same way as in (B), and are plotted. Closed and open circles represent signals
obtained with and without MNU treatment, respectively.
5708 Nucleic Acids Research, 2005, Vol. 33, No. 17Figure 4. Inability of MLH1- and MSH2-defective cells to form the protein complex. (A) Effect of MLH1 deficiency. HeLa MR (methyltransferase-deficient) and
SW48(deficientinbothmethyltransferaseandMLH1)cellsweretreatedwithorwithout1mMMNUfor1handthenwereincubatedforanother11h.Thechromatin
extracts were prepared as described in Figure 1 and the same amount of extracts were subjected to immunoprecipitation with an anti-MSH2 antibody, followed by
immunoblotting. (B) MSH2-dependent interaction of MutLa with PCNA. HeLa S3 and LoVo (MSH2-deficient) cells were pre-incubated in a medium containing
25 mM O
6-benzylguanine for 2 h and then exposed to MNU for 1 h. After incubation for another 11 h in the presence of O
6-benzylguanine, the chromatin extracts
were prepared, immunoprecipitated with the anti-PMS2 antibody, and immunoblotted.
Figure 5. EffectsofaPCNAknockdownontheformationofthemismatchrecognitioncomplexandtheapoptoticinduction.(A)PCNAknockdownbysiRNA.HeLa
MR(ePMS2)cellsweretransfectedwithsiRNAsforPCNAandnegativecontrolsequences,andthenwerecultivatedfor48h.Thewholecellextractspreparedwere
used for immunoblotting to analyze the total amounts of mismatch-related proteins. b-Actin is a loading control. (B) Chromatin-bound proteins under PCNA
knockdown condition. siRNA-transfected cells in (A) were treated with 1 mM MNU. After 12 h incubation, chromatin extracts were prepared and the amounts of
mismatch-related proteins and histone H3 were analyzed by immunoblotting. Histone H3 is a loading control. (C) Complex formation determined by immuno-
precipitationanalysis.Thechromatinextractswereusedforimmunoprecipitationwiththeanti-FLAGantibodyandthensubjectedto immunoblottingwiththeanti-
FLAG,MSH2,MLH1andPCNAantibodies.(D)Inductionofapoptosisasmeasuredbycaspase-3activity.Caspase-3activitywasdeterminedat72haftertreatment
withorwithout1mMMNU.ValuesobtainedwiththeMNU-treatedcellsweredividedbythoseoftheuntreatedcells,andtherelativecaspase-3activitiesareshown.
Experiments were performed three times and the standard deviations are shown in bars.
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There are two types of DNA lesions that cause apoptosis, one
that blocks DNA replication and another that allows progres-
sion of the DNA replication forks. Unless otherwise repaired,
both types of lesions can induce cell death, but in different
ways. Blockage of DNA replication by bulky DNA lesions is
sensed by the ATM/ATR system, which activates the
mitochondria-dependent apoptotic pathway for cell death
(36). However, modiﬁed bases, which allow DNA replication,
are recognized by a protein complex, composed of the bac-
terial mismatch repair protein homologs MutSa and MutLa,
to induce apoptosis (18,24). The latter process is of utmost
biological and medical signiﬁcance, since the survival of cells
carrying such mismatches wouldcause base substitution muta-
tions, leading to the induction of tumors and the disposition of
hereditary diseases.
Studies on the mechanism of apoptosis caused by
replication-permitting base mispairs have been hampered by
the lack of an appropriate in vivo system, since such mispairs
are rarely formed during the normal DNA replication. In vitro
reconstitution systems with synthetic DNA strands carrying
such mismatches have been devised, and protein complexes
interacting with the DNA fragments were isolated (37,38).
However, it was sometimes difﬁcult to analyze the relevant
roles of these complexes, found in vitro, in the induction
of apoptosis, since base mismatches would cause entirely dif-
ferent outcomes, including DNA repair, apoptosis and some
others, according to the conditions in vivo. In this regard,
O
6-methylguanine-induced mispairs are unique, since most
of the cells with these lesions undergo apoptosis (18).
O
6-methylguanine can be produced in the chromosomal
DNA in situ by exposing cells or organisms to simple alkylat-
ing agents and, moreover, the amount of the mismatched
bases in the DNA can be controlled by regulating the doses
of the agents. In the present study, we have taken advantage
of this system to identify a protein complex that interacts
with mismatched DNA under physiological conditions, in
which the protein interactions on the intact chromatin are
ﬁxed by a chemical crosslinker introduced into permeabilized
cells, and have related it to the induction of apoptosis.
When human cells deﬁcient in O
6-methylguanine-DNA
methyltransferase activity were exposed to appropriate
doses of MNU, a protein complex composed of PCNA,
MutSa and MutLa was formed on the chromosomal DNA.
Without exposure to the alkylating agent, no such complex
was formed. In normal cells, PCNA and MutSa exist as
forms associated with the chromatin, and this association
was observed even in cells that lack MLH1, a component
of MutLa. In the absence of MutSa, owing to the lack of
its component MSH2, no association of MutLa with the chro-
matin was achieved. Time course experiments revealed that
the formation of the PCNA–MutSa–MutLa complex occurs
gradually after MNU treatment and reaches a maximum of
 12 h after the treatment, implying that at least one cycle
of DNA replication is required for initiating the complex
Figure 6. Effectsofaphidicolinontheformationofthemismatchrecognitioncomplex.(A)Arrestofcellcycleprogressionbyaphidicolin.HeLaMR(ePMS2)cells
werecultivatedinamediumcontaining5mMaphidicolinfor16handthentreatedwith1mMMNUfor1h.Theculturewasdividedintotwoportions,oneincubated
in the presence of aphidicolin and the other in the absence of the drug. Cells were collected at the indicatedtime pointsand subjectedto flow cytometricanalyses to
monitor cell cycle progression. (B) Chromatin-bound PCNA during DNA replication. Chromatin extracts were prepared from cells at 0, 4 and 8 h after MNU
treatment,inthepresenceorabsenceofaphidicolin,andtheamountsofhistoneH3andPCNAwereanalyzedbyimmunoblotting.TherelativeratiosofPCNAarealso
shown. (C) Formation of protein complex during DNA replication. Chromatin extracts in (B) were used for immunoprecipitation with an anti-FLAG antibody.
Immunoblotting was performed with the anti-FLAG, MSH2, MLH1 and PCNA antibodies.
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the prevention of DNA replication by a treatment with aph-
idicolin, a DNA polymerase inhibitor, caused signiﬁcant
decrease in the levels of complex formation. After one
round of DNA replication, the O
6-methylguanine–cytosine
pair, produced by the action of alkylating agents, can be
converted to an O
6-methylguanine–thymine pair, which
may be the target for the MutSa–PCNA complex. Notably,
the pancytopenia observed in MNU-treated MGMT
 /  mice is
associated with the death of actively growing cells in bone
marrow and intestinal mucosa, and this impairment is com-
pletely suppressed by the introduction of the Mlh1 mutation
into the mice (5,17).
PCNA is a component of the DNA replication machinery,
and its role in mismatch repair has also been implicated. In
in vitro reconstitution experiments, physical interactions of
MutSa with PCNA were detected, and co-localization of
MutSa and PCNA in the nucleus was also shown (37,39–
41). In the present study, we found that PCNA persists on
the chromatin in a form associated with MutSa and, on the
exposure of cells to an alkylating agent, it further makes a
complex with MutLa. When siRNA for PCNA was intro-
duced, the amount of PCNA as well as those of the com-
ponents of MutSa and MutLa, forming the complex on
the chromatin, decreased considerably. Consistent with this
reduction, the induction of caspase-3, an event associated
with apoptosis, was signiﬁcantly suppressed. These results
support the view that PCNA is required for the progression
of O
6-methylguanine-induced apoptosis, in addition to its
fundamental roles in DNA replication and repair.
How is the O
6-methylguanine-triggered apoptosis exe-
cuted? The PCNA–MutSa complex may act as a genome
surveillant and bind to the O
6-methylguanine–thymine pair,
which is produced after one round of DNA replication. This
would then facilitate further binding of MutLa to the complex,
and the PCNA–MutSa–MutLa complex thus formed might
exert its action on certain molecules, which would transmit the
apoptotic signal to downstream members. Since the activation
of caspase-3 occurs during the course of O
6-methylguanine-
induced apoptosis (18), as observed in the processes triggered
by TNF and blockage of DNA replication forks (42,43),
it seems that the signals delivered from different sources
converge at the step of caspase-3 induction, which then activ-
ates the subsequent common steps necessary for the execution
of apoptosis, including DNA fragmentation and the formation
of apoptotic bodies. To understand the entire scheme of the
O
6-methylguanine-induced apoptotic pathway, the compon-
ents functioning downstream of mismatch repair proteins
must be identiﬁed. Studies aimed at elucidating this process
by both biochemical and genetical means are in progress in
the laboratory.
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